RNA Therapeutics Conference

Advances in delivery technologies and applications of RNA-based drugs for modulation of gene, protein expression and genome editing


London, United Kingdom

We announce the 10th Annual RNA Therapeutics Conference in London on February 20th - 21st 2019.

The field of RNA therapeutics is currently undergoing a major expansion, and the potential for using RNA drugs for personalised medicines and immunotherapy, as well as to address genetic, infectious and chronic diseases will ensure the continued development of RNA therapeutics for years to come.

Join us in February 2019, as our RNA Therapeutics Conference brings together industry experts from leading RNA therapeutics companies to discuss the challenges for clinical translation of RNA-based therapeutics, with an emphasis on recent advances in delivery technologies, and present an overview of the applications of RNA-based drugs for modulation of gene and protein expression, and genome editing.

Benefits of Attending

  • Discover the clinical progress of Spherical Nucleic Acids at Exicure
  • Understand Sanofi's strategies to deliver therapeutic oligonucleotides across biobarriers
  • Learn from ProQR how to plan for oligonucleotide supply from personalized medicine to large scale markets
  • Explore the development of small activating RNA - from bench to bedside with MiNA Therapeutics
  • Gain insight into the discovery and development of self-amplifying mRNA vaccines at GSK

Who should attend

Key Job Titles include:
  • Research & Development Directors/Managers/Scientists
  • Senior Scientists
  • Chief Scientific Officers
  • Chief Medical Officers
  • Heads of Clinical Development
  • Heads of Pre-Clinical Development

Speakers

  • Ali Murad, Director, Alnylam Pharmaceuticals UK & Ireland
  • Andre Gerber, Professor, RNA Biology, University Of Surrey
  • Bob Brown, Chief Scientific Officer, Senior Vice President, Dicerna Pharmaceuticals Inc.
  • Carsten Rudolf, Chief Executive Officer, Ethris GmbH
  • Daniel Zucker, Business Development Manager, NOF Europe GmbH
  • David Blakey, Chief Scientific Officer, MiNA Therapeutics
  • David Giljohann, CEO, Exicure Inc.
  • Ekkehard Leberer, Senior Director , Sanofi-Aventis Deutschland GmbH
  • Hans Kistemaker, Associate Director, ProQR
  • Henrich Haas, Vice President RNA Formulation & Drug Delivery, BioNTech RNA Pharmaceuticals
  • Ingmar Hoerr, Founder and CEO, Curevac Ag
  • Jeffrey Ulmer, Head Preclinical R&D, GSK
  • Kirsty Wydenbach, Deputy Unit Manager, Clinical Trials Unit, MHRA
  • Marian Gindy, Executive Director, MSD
  • Markus Mandler, Chief Scientific Officer, Accanis Biotech F&E GmbH & Co KG
  • Paul Agris, Director, The RNA Institute
  • Shalini Andersson, Senior Director and Head of New Modalities, AstraZeneca 
  • Steffen Panzner, Managing Director, Lipocalyx
  • Troels Koch, Vice President & Head of Research, RNA Therapeutics, Roche Innovation Center Copenhagen

Venue

Copthorne Tara Hotel
Scarsdale Place, Kensington
London, United Kingdom
RNA Therapeutics
Event details
Organizer : SMi Life Sciences
Venue : Copthorne Tara Hotel, London, United Kingdom
Event type : Conference
Reference : ASDE-19073